Please assess the completion status of the following clinical trial:

Trial Title: Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females who are 20 or over~* Patients who satisfy the classification criteria of Rheumatoid Arthritis according to American Colleague of Rheumatology (ACR 1987)~* Patients who are applicable to functional status I - III of American Colleague of Rheumatology~Exclusion Criteria:~* Patients who have autoimmune diseases other than rheumatoid arthritis or have significant secondary systematic disease caused by rheumatoid arthritis~* Patients who are currently participating in other clinical studies or receiving treatment for drugs not sold in the market or for experiment~* Patients who have significant other diseases that may affect the clinical trial when judged by the clinical trial Investigator~* In the opinion of the investigator, may put the patient at risk because of participation on the study or may influence the patients' ability to participate in the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HD203 (Type: EXPERIMENTAL): Subcutaneous injection (SC) HD203 25mg twice a week for 48 weeks
- Enbrel (Type: ACTIVE_COMPARATOR): Subcutaneous injection (SC) Enbrel® 25mg twice a week for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).